[â†’ Ø¨Ø®Ø´ Û¶-Û²: Ø´ÛŒØ±Ø¬Ù‡ Ø¨Ù‡ Ø¹Ù…Ù‚: Ù…Ù‚Ø¯Ù…Ù‡â€ŒØ§ÛŒ Ø¨Ø± ÛŒØ§Ø¯Ú¯ÛŒØ±ÛŒ Ø¹Ù…ÛŒÙ‚](./02-deep-dive-into-deep-learning.md) | [Ø¨Ø®Ø´ Û¶-Û´: Ø§Ø®Ù„Ø§Ù‚ Ø¯Ø± Ù‡ÙˆØ´ Ù…ØµÙ†ÙˆØ¹ÛŒ Ø²ÛŒØ³ØªÛŒ: ÙØ±Ø§ØªØ± Ø§Ø² Ú©Ø¯ â†](./04-ethics-in-bio-ai.md)

# ÙØµÙ„ Û¶: Ù…Ø¨Ø§Ø­Ø« Ù¾ÛŒØ´Ø±ÙØªÙ‡ Ùˆ Ú©Ø§Ø±Ø¨Ø±Ø¯Ù‡Ø§ÛŒ Ø¯Ù†ÛŒØ§ÛŒ ÙˆØ§Ù‚Ø¹ÛŒ

## Ø¨Ø®Ø´ Û¶-Û³: Ù…Ø·Ø§Ù„Ø¹Ù‡ Ù…ÙˆØ±Ø¯ÛŒ: Ø·Ø±Ø§Ø­ÛŒ Ù…ÙˆÙ„Ú©ÙˆÙ„â€ŒÙ‡Ø§ÛŒ Ø¯Ø§Ø±Ùˆ Ø¨Ø§ Ù‡ÙˆØ´ Ù…ØµÙ†ÙˆØ¹ÛŒ

ØªØ§ Ú©Ù†ÙˆÙ† Ø¯Ø± Ú©ØªØ§Ø¨ Ù…Ø§ Ø¨Ø§ Ú©Ø§Ø±Ø¨Ø±Ø¯Ù‡Ø§ÛŒ Â«Ù¾ÛŒØ´â€ŒØ¨ÛŒÙ†ÛŒÂ» (Prediction) Ø¯Ø± Ø¨ÛŒÙˆØ§Ù†ÙÙˆØ±Ù…Ø§ØªÛŒÚ© Ùˆ Ù¾Ø²Ø´Ú©ÛŒ Ø¢Ø´Ù†Ø§ Ø´Ø¯Ù‡â€ŒØ§ÛŒÙ…ØŒ Ø§Ø² ØªØ´Ø®ÛŒØµ Ø³Ø±Ø·Ø§Ù† ØªØ§ Ø¨Ø±Ø¢ÙˆØ±Ø¯ ØªÙ…Ø§ÛŒÙ„ Ø§ØªØµØ§Ù„ Ø¯Ø§Ø±ÙˆÙ‡Ø§. Ø§Ù…Ø§ ÛŒÚ©ÛŒ Ø§Ø² Ù…Ø±Ø²Ù‡Ø§ÛŒ Ù†ÙˆØ¸Ù‡ÙˆØ± Ù‡ÙˆØ´ Ù…ØµÙ†ÙˆØ¹ÛŒØŒ ØªÙˆØ§Ù†Ø§ÛŒÛŒ Â«Ø®Ù„Ù‚ Ú©Ø±Ø¯Ù†Â» (Generation) Ø§Ø³ØªØ› Ø¨Ù‡ Ú©Ù…Ú© **Generative Models** Ù…ÛŒâ€ŒØªÙˆØ§Ù† Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§ÛŒ Ú©Ø§Ù…Ù„Ø§Ù‹ Ø¬Ø¯ÛŒØ¯ÛŒ ØªÙˆÙ„ÛŒØ¯ Ú©Ø±Ø¯ Ú©Ù‡ Ø®ÙˆØ§Øµ Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§ÛŒ Ø¢Ù…ÙˆØ²Ø´ÛŒ Ø±Ø§ ØªÙ‚Ù„ÛŒØ¯ Ù…ÛŒâ€ŒÚ©Ù†Ù†Ø¯. Ø§ÛŒÙ† ØªÙˆØ§Ù†Ø§ÛŒÛŒ Ø§Ù†Ù‚Ù„Ø§Ø¨ÛŒ Ø¯Ø± Ø­ÙˆØ²Ù‡ Ø·Ø±Ø§Ø­ÛŒ Ø¯Ø§Ø±Ùˆ Ø§ÛŒØ¬Ø§Ø¯ Ú©Ø±Ø¯Ù‡ Ø§Ø³Øª.

### ðŸŽ¯ Ù…Ø³Ø¦Ù„Ù‡ Ù…Ø­ÙˆØ±ÛŒ: Ø¢ÛŒØ§ Ù‡ÙˆØ´ Ù…ØµÙ†ÙˆØ¹ÛŒ Ù…ÛŒâ€ŒØªÙˆØ§Ù†Ø¯ Ø¨Ù‡ Ø¬Ø§ÛŒ Â«Ù¾ÛŒØ´â€ŒØ¨ÛŒÙ†ÛŒÂ»ØŒ Â«Ø®Ù„Ù‚Â» Ú©Ù†Ø¯ØŸ

Ø¨Ù‡ Ø¬Ø§ÛŒ ØºØ±Ø¨Ø§Ù„Ú¯Ø±ÛŒ Ù…ÛŒÙ„ÛŒÙˆÙ†â€ŒÙ‡Ø§ Ù…ÙˆÙ„Ú©ÙˆÙ„ Ø´Ù†Ø§Ø®ØªÙ‡â€ŒØ´Ø¯Ù‡ØŒ Ù…ÛŒâ€ŒØªÙˆØ§Ù†ÛŒÙ… Ø§Ø² Ù…Ø¯Ù„ Ù…ÙˆÙ„Ø¯ Ø¨Ø®ÙˆØ§Ù‡ÛŒÙ…:  
Â«ÛŒÚ© Ù…ÙˆÙ„Ú©ÙˆÙ„ Ø¬Ø¯ÛŒØ¯ Ø·Ø±Ø§Ø­ÛŒ Ú©Ù† Ú©Ù‡ ÙˆÛŒÚ˜Ú¯ÛŒâ€ŒÙ‡Ø§ÛŒ Ø²ÛŒØ± Ø±Ø§ Ø¯Ø§Ø´ØªÙ‡ Ø¨Ø§Ø´Ø¯ Ùˆ Ø³Ù…ÛŒ Ù†Ø¨Ø§Ø´Ø¯.Â»  
Ø¯Ø± Ø§ÛŒÙ† Ù…Ø·Ø§Ù„Ø¹Ù‡ØŒ Ø¨Ø§ ÛŒÚ©ÛŒ Ø§Ø² Ù…Ù‡Ù…â€ŒØªØ±ÛŒÙ† Ù†Ù…ÙˆÙ†Ù‡â€ŒÙ‡Ø§ÛŒ **AI-driven drug design** Ø¢Ø´Ù†Ø§ Ù…ÛŒâ€ŒØ´ÙˆÛŒÙ….

### Ø¯Ø§Ø³ØªØ§Ù† Ù…ÙˆÙÙ‚ÛŒØª: Ø¯Ø§Ø±ÙˆÛŒ Rentosertib Ø¨Ø±Ø§ÛŒ ÙÛŒØ¨Ø±ÙˆØ² Ø±ÛŒÙˆÛŒ Ø§ÛŒØ¯ÛŒÙˆÙ¾Ø§ØªÛŒÚ©

Ø¯Ø§Ø±ÙˆÛŒ **Rentosertib** (ISM001-055) Ù†Ø®Ø³ØªÛŒÙ† Ø¯Ø§Ø±ÙˆÛŒÛŒ Ø§Ø³Øª Ú©Ù‡ Ù‡Ù… Â«Ù‡Ø¯Ù Ø¯Ø§Ø±ÙˆÛŒÛŒÂ» (drug target) Ùˆ Ù‡Ù… Ù…ÙˆÙ„Ú©ÙˆÙ„ Ø¹Ù…Ù„â€ŒÚ©Ù†Ù†Ø¯Ù‡ (small-molecule) Ø¢Ù† Ú©Ø§Ù…Ù„Ø§Ù‹ ØªÙˆØ³Ø· Ù‡ÙˆØ´ Ù…ØµÙ†ÙˆØ¹ÛŒ Ú©Ø´Ù Ùˆ Ø·Ø±Ø§Ø­ÛŒ Ø´Ø¯Ù‡â€ŒØ§Ù†Ø¯[1][2]:

1. **Ú©Ø´Ù Ù‡Ø¯Ù Ø¬Ø¯ÛŒØ¯**  
   Ù¾Ù„ØªÙØ±Ù… **PandaOmics** Ø¨Ø§ ØªØ­Ù„ÛŒÙ„ Ú†Ù†Ø¯ÛŒÙ† Ù„Ø§ÛŒÙ‡ Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§ÛŒ Ø§ÙˆÙ…ÛŒÚ©Ø³ Ùˆ Ù…ØªÙˆÙ† Ø¨ÛŒÙˆÙ…Ø¯ÛŒÚ©Ø§Ù„ØŒ Ú©ÛŒÙ†Ø§Ø² Ø¬Ø¯ÛŒØ¯ **TNIK** (TRAF2- and NCK-interacting kinase) Ø±Ø§ Ø¨Ù‡ Ø¹Ù†ÙˆØ§Ù† Ø¹Ø§Ù…Ù„ Ú©Ù„ÛŒØ¯ÛŒ Ø¯Ø± ÙÛŒØ¨Ø±ÙˆØ² Ø±ÛŒÙˆÛŒ Ø§ÛŒØ¯ÛŒÙˆÙ¾Ø§ØªÛŒÚ© Ø´Ù†Ø§Ø³Ø§ÛŒÛŒ Ú©Ø±Ø¯[3][4].

2. **Ø·Ø±Ø§Ø­ÛŒ Ù…ÙˆÙ„Ú©ÙˆÙ„ Ø¬Ø¯ÛŒØ¯**  
   Ù¾Ù„ØªÙØ±Ù… Ù…ÙˆÙ„Ø¯ **Chemistry42** Ø§Ø² Ù…Ø¹Ù…Ø§Ø±ÛŒâ€ŒÙ‡Ø§ÛŒ Ù…Ø®ØªÙ„ÙÛŒ Ø´Ø§Ù…Ù„ GANØŒ AutoencoderØŒ flow-based Ùˆ language models Ø¨Ù‡Ø±Ù‡ Ù…ÛŒâ€ŒØ¨Ø±Ø¯ ØªØ§ Ø§Ø² ØµÙØ± Ù…ÙˆÙ„Ú©ÙˆÙ„ÛŒ Ø¨Ø§ ÙˆÛŒÚ˜Ú¯ÛŒâ€ŒÙ‡Ø§ÛŒ Ø¨Ù‡ÛŒÙ†Ù‡ (Ù†Ú¯Ù‡Ø¯Ø§Ø±ÛŒ Ø­Ù„Ø§Ù„ÛŒØª Ù…Ù†Ø§Ø³Ø¨ØŒ Ø³Ù…ÛŒØª Ù¾Ø§ÛŒÛŒÙ† Ùˆ Ø§ØªØµØ§Ù„ Ù‚ÙˆÛŒ Ø¨Ù‡ TNIK) ØªÙˆÙ„ÛŒØ¯ Ú©Ù†Ø¯[5][6].

> Ø§Ø² Ú©Ø´Ù Ù‡Ø¯Ù ØªØ§ Ø§ÙˆÙ„ÛŒÙ† Ø¢Ø²Ù…Ø§ÛŒØ´ Ø§Ù†Ø³Ø§Ù†ÛŒØŒ Ú©Ù…ØªØ± Ø§Ø² Û³Û° Ù…Ø§Ù‡ Ø·ÙˆÙ„ Ú©Ø´ÛŒØ¯â€”Ø¯Ø± Ø­Ø§Ù„ÛŒ Ú©Ù‡ Ø±ÙˆØ´â€ŒÙ‡Ø§ÛŒ Ø³Ù†ØªÛŒ Û±Û°â€“Û±Ûµ Ø³Ø§Ù„ Ø²Ù…Ø§Ù†â€ŒØ¨Ø± Ø§Ø³Øª[1].

#### Ù†ØªØ§ÛŒØ¬ Ø§ÙˆÙ„ÛŒÙ‡ ÙØ§Ø² IIa

Ø¯Ø± Ù…Ø·Ø§Ù„Ø¹Ù‡ ÙØ§Ø² IIa (NCT05938920) Ø±ÙˆÛŒ Û·Û± Ø¨ÛŒÙ…Ø§Ø±ØŒ Ú¯Ø±ÙˆÙ‡ Ø¯Ø±ÛŒØ§ÙØªâ€ŒÚ©Ù†Ù†Ø¯Ù‡ Û¶Û° Ù…ÛŒÙ„ÛŒâ€ŒÚ¯Ø±Ù… Rentosertib ÛŒÚ© Ø¨Ù‡Ø¨ÙˆØ¯ Ù…ÛŒØ§Ù†Ú¯ÛŒÙ† +Û¹Û¸.Û´ Ù…ÛŒÙ„ÛŒâ€ŒÙ„ÛŒØªØ± Ø¯Ø± **Forced Vital Capacity** Ø¯Ø§Ø´ØªÙ†Ø¯ØŒ Ø¯Ø± Ù…Ù‚Ø§Ø¨Ù„ âˆ’Û²Û°.Û³ Ù…ÛŒÙ„ÛŒâ€ŒÙ„ÛŒØªØ± Ø¯Ø± Ú¯Ø±ÙˆÙ‡ Ù¾Ù„Ø§Ø³Ø¨Ùˆ[7][1][2]. Ù‡Ù…Ú†Ù†ÛŒÙ† Ú©Ø§Ù‡Ø´ Ù†Ø´Ø§Ù†Ú¯Ø±Ù‡Ø§ÛŒ Ø¨ÛŒÙˆÙ„ÙˆÚ˜ÛŒÚ© ÙÛŒØ¨Ø±ÙˆØªÛŒÚ© Ùˆ Ø§ÙØ²Ø§ÛŒØ´ Ø³ÛŒØªÙˆÚ©ÛŒÙ†â€ŒÙ‡Ø§ÛŒ Ø¶Ø¯Ø§Ù„ØªÙ‡Ø§Ø¨ÛŒ Ú¯Ø²Ø§Ø±Ø´ Ø´Ø¯[7].

### Ù…Ø¯Ù„â€ŒÙ‡Ø§ÛŒ Ù…ÙˆÙ„Ø¯ Ú†Ú¯ÙˆÙ†Ù‡ Ø¹Ù…Ù„ Ù…ÛŒâ€ŒÚ©Ù†Ù†Ø¯ØŸ Ø¢Ù†Ø§Ù„ÙˆÚ˜ÛŒ Â«Ø¬Ø§Ø¹Ù„ Ùˆ Ú©Ø§Ø±Ø¢Ú¯Ø§Ù‡Â»

Ù…Ø¹Ù…Ø§Ø±ÛŒ Ø±Ø§ÛŒØ¬ Ø¯Ø± **Generative Adversarial Networks (GANs)** Ø¨Ø± Ù¾Ø§ÛŒÙ‡ ÛŒÚ© Ø¨Ø§Ø²ÛŒ Ø¯Ùˆ Ø´Ø¨Ú©Ù‡ Ø§Ø³Øª:

- **Ø´Ø¨Ú©Ù‡ Ù…ÙˆÙ„Ø¯ (The Forger / Ø¬Ø§Ø¹Ù„):** Ø³Ø§Ø®Øª Ù…ÙˆÙ„Ú©ÙˆÙ„â€ŒÙ‡Ø§ÛŒ Ø¬Ø¯ÛŒØ¯
- **Ø´Ø¨Ú©Ù‡ ØªÙ…Ø§ÛŒØ²Ø¯Ù‡Ù†Ø¯Ù‡ (The Detective / Ú©Ø§Ø±Ø¢Ú¯Ø§Ù‡):** ØªÙ…Ø§ÛŒØ² Ù…ÙˆÙ„Ú©ÙˆÙ„â€ŒÙ‡Ø§ÛŒ ÙˆØ§Ù‚Ø¹ÛŒ Ø§Ø² Ø¬Ø¹Ù„ÛŒ

Ø§ÛŒÙ† Ø¯Ùˆ Ø´Ø¨Ú©Ù‡ Ø¯Ø± ÛŒÚ© Ú†Ø±Ø®Ù‡ ÛŒØ§Ø¯Ú¯ÛŒØ±ÛŒ Ø±Ù‚Ø§Ø¨ØªÛŒØŒ Ø¨Ù‡Ø¨ÙˆØ¯ Ù…ÛŒâ€ŒÛŒØ§Ø¨Ù†Ø¯ ØªØ§ Ù…ÙˆÙ„Ú©ÙˆÙ„â€ŒÙ‡Ø§ÛŒ Ø¬Ø¹Ù„ÛŒ Ú©Ø§Ù…Ù„Ø§Ù‹ ÙˆØ§Ù‚Ø¹â€ŒÚ¯Ø±Ø§ÛŒØ§Ù†Ù‡ Ø´ÙˆÙ†Ø¯.

```mermaid
graph TD
    A[Ù†ÙˆÛŒØ² ØªØµØ§Ø¯ÙÛŒ] --> B(Ø´Ø¨Ú©Ù‡ Ù…ÙˆÙ„Ø¯"Ø¬Ø§Ø¹Ù„");
    B -- "Ù…ÙˆÙ„Ú©ÙˆÙ„ Ø¬Ø¹Ù„ÛŒ" --> D{Ø´Ø¨Ú©Ù‡ ØªÙ…Ø§ÛŒØ²Ø¯Ù‡Ù†Ø¯Ù‡"Ú©Ø§Ø±Ø¢Ú¯Ø§Ù‡"};
    C[Ù¾Ø§ÛŒÚ¯Ø§Ù‡ Ø¯Ø§Ø¯Ù‡ Ù…ÙˆÙ„Ú©ÙˆÙ„â€ŒÙ‡Ø§ÛŒ ÙˆØ§Ù‚Ø¹ÛŒ] -- "Ù…ÙˆÙ„Ú©ÙˆÙ„ ÙˆØ§Ù‚Ø¹ÛŒ" --> D;
    D -- "Ø¨Ø§Ø²Ø®ÙˆØ±Ø¯: ÙˆØ§Ù‚Ø¹ÛŒ ÛŒØ§ Ø¬Ø¹Ù„ÛŒ" --> B;
```

### ðŸ”¬ ØªÙ…Ø±ÛŒÙ† ØªØ­Ù„ÛŒÙ„ÛŒ: ØªÙÚ©Ø± Ù…ÙˆÙ„Ø¯

Ø´Ù…Ø§ Ù…Ø¯ÛŒØ± Ù¾Ø±ÙˆÚ˜Ù‡â€ŒØ§ÛŒ Ù‡Ø³ØªÛŒØ¯ Ú©Ù‡ Ù…Ø¯Ù„ GAN Ø±Ø§ Ø¨Ø±Ø§ÛŒ ØªÙˆÙ„ÛŒØ¯ Ø³Ø§Ø®ØªØ§Ø±Ù‡Ø§ÛŒ Ù…ÙˆÙ„Ú©ÙˆÙ„ÛŒ Ø¢Ù…ÙˆØ²Ø´ Ø¯Ø§Ø¯Ù‡ Ø§Ø³Øª. Ø§Ú©Ù†ÙˆÙ† Ø¨Ø§ÛŒØ¯ Ú¯Ø±Ø¯Ø´ Ú©Ø§Ø±ÛŒ Ø·Ø±Ø§Ø­ÛŒ Ú©Ù†ÛŒØ¯ ØªØ§ Ø¨Ø§ Ù…Ø¯Ù„â€ŒÙ‡Ø§ÛŒ Ù¾ÛŒØ´â€ŒØ¨ÛŒÙ†ÛŒâ€ŒÚ©Ù†Ù†Ø¯Ù‡ØŒ Ù…ÛŒÙ„ÛŒÙˆÙ†â€ŒÙ‡Ø§ Ù…ÙˆÙ„Ú©ÙˆÙ„ ØªÙˆÙ„ÛŒØ¯Ø´Ø¯Ù‡ Ø±Ø§ ØºØ±Ø¨Ø§Ù„Ú¯Ø±ÛŒ Ú©Ù†ÛŒØ¯ Ùˆ Ø¨Ù‡ØªØ±ÛŒÙ†â€ŒÙ‡Ø§ Ø±Ø§ Ø¨Ø±Ø§ÛŒ Ø³Ù†ØªØ² Ø§Ù†ØªØ®Ø§Ø¨ Ù†Ù…Ø§ÛŒÛŒØ¯.

**Ù¾Ø§Ø³Ø® Ù†Ù…ÙˆÙ†Ù‡:**

| Ù…Ø±Ø­Ù„Ù‡     | Ù…Ø¯Ù„ Ù¾ÛŒØ´â€ŒØ¨ÛŒÙ†ÛŒâ€ŒÚ©Ù†Ù†Ø¯Ù‡      | Ù¾ÛŒØ´â€ŒØ¨ÛŒÙ†ÛŒâ€ŒÙ‡Ø§                                                       | Ù…Ø¹ÛŒØ§Ø± Ø§Ù†ØªØ®Ø§Ø¨                                                      |
| --------- | ----------------------- | ----------------------------------------------------------------- | ----------------------------------------------------------------- |
| Û±         | Ù…Ø¯Ù„â€ŒÙ‡Ø§ÛŒ Ø±Ú¯Ø±Ø³ÛŒÙˆÙ†         | Ø­Ù„Ø§Ù„ÛŒØª (Solubility)ØŒ ÙˆØ²Ù† Ù…ÙˆÙ„Ú©ÙˆÙ„ÛŒØŒ Ø¨Ø±Ø¢ÙˆØ±Ø¯ Ù¾ÛŒØ±ÙˆÛŒ Ø§Ø² Ù‚ÙˆØ§Ù†ÛŒÙ† Ù„ÛŒÙ¾ÛŒÙ†Ø³Ú©ÛŒ | Ø­Ù„Ø§Ù„ÛŒØª > Ø¢Ø³ØªØ§Ù†Ù‡ Ù…Ø´Ø®ØµØŒ ÙˆØ²Ù† Ù…ÙˆÙ„Ú©ÙˆÙ„ÛŒ < 500 Ø¯Ø§Ù„ØªÙˆÙ†ØŒ Ø§Ù…ØªÛŒØ§Ø² Lipinskiâ‰¥3 |
| Û²         | Ù…Ø¯Ù„ Ø±Ú¯Ø±Ø³ÛŒÙˆÙ† ØªÙ…Ø§ÛŒÙ„ Ø§ØªØµØ§Ù„ | pIC50 Ø¨Ø±Ø§ÛŒ Ø§ØªØµØ§Ù„ Ø¨Ù‡ TNIK                                          | Ø§Ù†ØªØ®Ø§Ø¨ Û±Û°Û°Û° Ù…ÙˆÙ„Ú©ÙˆÙ„ Ø¨Ø§ Ø¨Ø§Ù„Ø§ØªØ±ÛŒÙ† pIC50                              |
| Û³         | Ù…Ø¯Ù„ Ø·Ø¨Ù‚Ù‡â€ŒØ¨Ù†Ø¯ÛŒ Ø³Ù…ÛŒØª      | Ø§Ø­ØªÙ…Ø§Ù„ Ø§ØªØµØ§Ù„ Ø¨Ù‡ Ú©Ø§Ù†Ø§Ù„â€ŒÙ‡Ø§ÛŒ hERG                                    | Ø§Ø­ØªÙ…Ø§Ù„ Ø³Ù…ÛŒØª < Û±Û°Ùª Ø¯Ø± Ø¨ÛŒÙ† Û±Û°Û°Û° Ù…ÙˆÙ„Ú©ÙˆÙ„                              |
| **Ù†ØªÛŒØ¬Ù‡** | â€”                       | â€”                                                                 | ÛµÛ°â€“Û±Û°Û° Ú©Ø§Ù†Ø¯ÛŒØ¯Ø§ÛŒ Ù†Ù‡Ø§ÛŒÛŒ Ø¨Ø±Ø§ÛŒ Ø³Ù†ØªØ² Ø¢Ø²Ù…Ø§ÛŒØ´Ú¯Ø§Ù‡ÛŒ                        |

### ðŸ’¡ Ù†Ú©Ø§Øª Ú©Ù„ÛŒØ¯ÛŒ Ø§ÛŒÙ† Ø¨Ø®Ø´

- **Generative Models:** Ø®Ù„Ù‚ Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§ÛŒ Ú©Ø§Ù…Ù„Ø§Ù‹ Ø¬Ø¯ÛŒØ¯ (Ù…Ø§Ù†Ù†Ø¯ Ø³Ø§Ø®ØªØ§Ø±Ù‡Ø§ÛŒ Ù…ÙˆÙ„Ú©ÙˆÙ„ÛŒ)
- **De Novo Drug Design:** Ø·Ø±Ø§Ø­ÛŒ Ù…ÙˆÙ„Ú©ÙˆÙ„ Ø§Ø² ØµÙØ± Ø¨Ù‡ Ø¬Ø§ÛŒ ØºØ±Ø¨Ø§Ù„Ú¯Ø±ÛŒ Ù„ÛŒØ³Øªâ€ŒÙ‡Ø§ÛŒ Ù…ÙˆØ¬ÙˆØ¯
- **GAN:** Ø±Ù‚Ø§Ø¨Øª Ø¬Ø§Ø¹Ù„ Ùˆ Ú©Ø§Ø±Ø¢Ú¯Ø§Ù‡ Ø¨Ø±Ø§ÛŒ ØªÙˆÙ„ÛŒØ¯ Ø¯Ø§Ø¯Ù‡â€ŒÙ‡Ø§ÛŒ ÙˆØ§Ù‚Ø¹â€ŒÚ¯Ø±Ø§ÛŒØ§Ù†Ù‡
- **Ú¯Ø±Ø¯Ø´ Ú©Ø§Ø± Ú©Ø´Ù Ø¯Ø§Ø±Ùˆ Ø¨Ø§ AI:**
  1. Ú©Ø´Ù Ù‡Ø¯Ù
  2. ØªÙˆÙ„ÛŒØ¯ Ù…ÙˆÙ„Ú©ÙˆÙ„
  3. ÙÛŒÙ„ØªØ± Ùˆ Ø§Ø±Ø²ÛŒØ§Ø¨ÛŒ
  4. Ø³Ù†ØªØ² Ùˆ ØªØ³Øª Ø¢Ø²Ù…Ø§ÛŒØ´Ú¯Ø§Ù‡ÛŒ

**Ù…Ø²ÛŒØª:** ØªØ³Ø±ÛŒØ¹ Ú†Ø´Ù…Ú¯ÛŒØ± Ú©Ø´Ù Ø¯Ø§Ø±Ùˆ Ùˆ Ø§Ù…Ú©Ø§Ù† Ú©Ø§ÙˆØ´ Ø¯Ø± ÙØ¶Ø§ÛŒâ€ŒÙ‡Ø§ÛŒ Ø´ÛŒÙ…ÛŒØ§ÛŒÛŒ Ù†ÙˆÛŒÙ†.

Ø§ÛŒÙ† Ù…Ø·Ø§Ù„Ø¹Ù‡ Ù…ÙˆØ±Ø¯ÛŒ Ù†Ø´Ø§Ù† Ù…ÛŒâ€ŒØ¯Ù‡Ø¯ Ú©Ù‡ Ù‡ÙˆØ´ Ù…ØµÙ†ÙˆØ¹ÛŒ Ù†Ù‡â€ŒØªÙ†Ù‡Ø§ Ø¨Ù‡â€ŒØ¹Ù†ÙˆØ§Ù† Ø§Ø¨Ø²Ø§Ø± Ù¾ÛŒØ´â€ŒØ¨ÛŒÙ†ÛŒØŒ Ø¨Ù„Ú©Ù‡ Ø¨Ù‡â€ŒØ¹Ù†ÙˆØ§Ù† ÛŒÚ© Â«Ø®Ø§Ù„Ù‚Â» Ù…ÙˆÙ„Ú©ÙˆÙ„â€ŒÙ‡Ø§ÛŒ Ø¯Ø§Ø±ÙˆÛŒÛŒ Ù†Ù‚Ø´â€ŒØ¢ÙØ±ÛŒÙ†ÛŒ Ù…ÛŒâ€ŒÚ©Ù†Ø¯ Ùˆ Ù…ÛŒâ€ŒØªÙˆØ§Ù†Ø¯ Ù…Ø³ÛŒØ± Ú©Ø´Ù Ø¯Ø§Ø±Ùˆ Ø±Ø§ Ø¨Ù‡â€ŒØ´Ú©Ù„ Ø¨Ù†ÛŒØ§Ø¯ÛŒÙ†ÛŒ ØªØºÛŒÛŒØ± Ø¯Ù‡Ø¯.

---

## **Ù…Ù†Ø§Ø¨Ø¹**

[1] https://www.prnewswire.com/news-releases/insilico-medicine-announces-nature-medicine-publication-of-phase-iia-results-evaluating-rentosertib-the-novel-tnik-inhibitor-for-idiopathic-pulmonary-fibrosis-ipf-discovered-and-designed-with-a-pioneering-ai-approach-302472070.html
[2] https://pubmed.ncbi.nlm.nih.gov/40461817/
[3] https://pubs.acs.org/doi/10.1021/acs.jcim.3c01619
[4] https://www.nature.com/articles/s41587-024-02143-0
[5] https://pmc.ncbi.nlm.nih.gov/articles/PMC9930109/
[6] https://arxiv.org/pdf/2101.09050.pdf
[7] https://www.genengnews.com/topics/artificial-intelligence/insilico-eyes-q4-start-for-late-stage-trials-of-ipf-candidate/
[8] https://www.drugtargetreview.com/news/157365/first-ai-designed-drug-rentosertib-named-by-usan/
[9] https://pharma.ai/pandaomics
[10] https://www.drugdiscoverytrends.com/ai-identified-fibrosis-target-advances-ipf-drug/
[11] https://pubs.acs.org/doi/10.1021/acs.jcim.2c01191
[12] https://www.drugdiscoverytrends.com/insilicos-ai-designed-rentosertib-shows-promise-in-first-phase-2a-trial-results/
[13] https://insilico.com/news/tnik-ipf-phase2a
[14] https://www.youtube.com/watch?v=3Dujv4z1oUQ
[15] https://pharma.ai/chemistry42
[16] https://insilico.com/pipeline_target_targetx
[17] https://communities.springernature.com/posts/ai-meets-ipf-taking-an-ai-designed-drug-from-target-discovery-to-phase-iia
[18] https://insilico.com/chemistry42_fr
[19] https://www.nature.com/articles/s41591-025-03743-2
[20] https://www.bohrium.com/paper-details/chemistry42-an-ai-driven-platform-for-molecular-design-and-optimization/864965814078406930-3424
